Home > Boards > US Listed > Medical - Drugs >

BioPharmX Corp. (BPMX)

Add BPMX Price Alert      Hide Sticky   Hide Intro
Moderator: Whos_Who
Search This Board: 
Last Post: 5/20/2019 3:35:13 PM - Followers: 109 - Board type: Free - Posts Today: 0


Biodelivery that makes a difference! 

BioPharmX Corporation was created to fulfill the unmet medical needs of people worldwide. To achieve that, we take a disciplined approach to research and product development. Our scientists, researchers, marketers and other team members are mission driven, committed to producing novel treatments to cure intractable medical conditions.

We focus exclusively on dermatological issues and women’s health. We seek to develop therapeutic products that provide unique solutions to common medical problems in these areas. Our approach is to create novel mechanisms to deliver effective treatments for persistent and often debilitating conditions.

In dermatology, for example, we are developing a unique way to deliver acne-fighting medicine topically. Today’s most effective acne medications must be ingested, risking undesirable side-effects. Topical treatments tend to be ineffective because their formulations do not deliver medication to the layer of skin where acne forms. Our developmental topical, called BPX-01, effectively delivers small amounts of antibiotic to the acne source, maximizing treatment effectiveness and reducing side-effects.

In women’s health, we are currently focused on improving breast health by treating fibrocystic breast condition, a medical problem that affects half the world’s women. The condition, which often produces breast tenderness and tissue density, can be treated with molecular iodine, which is effective but rarely found in a stable form. Our solution is Violet® iodine, a daily supplement that produces molecular iodine within the body – exactly where it can be most effective.

Both of these solutions demonstrate the power of BioPharmX’s unique combination of innovation and determination.

We develop unique health and wellness products for licensing and commercialization in pharmaceutical and over-the-counter use.



By design, BioPharmX's innovative drug delivery products, with their unique patented platform technologies, are formulated to address the needs of well-defined, fast-growing, multi-billion dollar markets, including dermatology, aesthetics, otolaryngology (ears, nose & throat), and women’s health.


Violet Iodine
A revolution in women’s breast health.

It’s a daily regimen that alleviates the symptoms you experience with your monthly cycle – like breast tenderness, aches, heaviness and swelling*. Violet iodine doesn’t just mask the discomfort temporarily; it actually promotes better breast health*. When you take a simple pill every day the result is true relief and reassurance that you’re proactively taking care of your breasts.

BioPharmX aims to be a leader in its understanding of the science of the skin.

Currently in phase 2 of clinical development, BPX-01 may offer a breakthrough in acne treatment because it can deliver the antibiotic to the area of the skin where acne develops. The novel hydrophilic (non oil-based) formulation of minocycline may be more effective than other topical alternatives because they either use less effective antibiotics to penetrate the top layer of the skin or rely on higher concentrations of minocycline, which could lead to unpleasant side effects.

BPX-01 is the first and only stable hydrophilic topical gel with fully solubilized minocycline. Minocycline, an antibacterial and anti-inflammatory medicine, is the most commonly prescribed acne treatment because it has a lower resistance rate than other antibiotics. No stable form of hydrophilic topical minocycline is currently commercially available.

  Delivery Pathways

  BioPharmX creates unique drug delivery products for IP licensing or direct commercialization for pharmaceutical, over-the-counter, and supplement distribution and sales.


Product Types

Our unique health and wellness products (for licensing and commercialization in pharmaceutical and over-the-counter (OTC) use) leverage our extensive experience in pharmacological and biological sciences and drug delivery product development. Our team is experienced in performing pre-clinical studies focused on analytics, pharmacokinetics and toxicology, experimental design, and investigational protocols. We do this through product research and development and through strategic partnerships with leading worldwide pharmaceutical companies.

Our commitment to providing customers with products that improve the quality of their lives can only be met through unrivaled innovation and a dedication to quality—both of which are integral parts of BioPharmX's company culture.


            Over the Counter Products        


With significant investments in R&D and a deep background in pharmaceutical and medical device development, BioPharmX is uniquely positioned to bring leading-edge, over-the-counter (OTC) products to the retail marketplace. Our products all meet rigorous internal quality measurements and leverage the capabilities required for pharmaceutical grade FDA products. 


BioPharmX enables innovative solutions by working with pharmaceutical companies worldwide to achieve shorter time-to-market scenarios. We do this through a suite of core competencies unique to our teams:

♦ Customized solutions to fit drug formulation needs
♦ Expertise in regulatory, toxicology and clinical studies
♦ Streamlined pathways through development
♦ Unrivaled commitment to quality





BioPharmX currently has multiple products in various stages of development for therapeutic drug delivery in the areas of women's health, dermatology, aesthetics and ENT.




Our R&D team specializes in developing world-class clinical studies. They perform formulation development, outline safety profiles and dosing requirements, and set validation protocols. Currently they are developing a portfolio of patented drug applications (including novel formulations and minimally invasive delivery devices in respective markets) to be out-licensed or commercialized.


"Biopharmx's first product violet will hit market this fall"
"This company is a $$ maker." 




BioPharmX partners with leading pharmaceutical companies through regulatory approval or performs all activities internally, utilizing our team of regulatory and product development experts. Our partners turn to us to enhance delivery characteristics to improve drug performance and patient compliance. Our proven methods and technologies provide our customers with unique and measurable technical and competitive advantages.



Management Team

The BioPharmX management team consists of Silicon Valley executives, scientists and business professionals combining large company discipline with deep biotech expertise focused on drug delivery and molecular properties. The team has the proven ability to raise capital and streamline new technologies into viable, marketable and successful products.



Jim Pekarsky     Resigned , effective May 11, 2016                                                                                                                     

Mr. Pekarsky has devoted over 30 years to growing diverse medical research and high-tech companies, including Bio Rad Laboratories, Mentor Graphics, MoSys and Virage Logic. He has spent over 10 years as the Chief Financial Officer of several public and private companies and five years as a European General Manager for U.S. multinational corporations. For more than a decade he has been counseling start-ups in Silicon Valley and leading their financings, acquisitions and initial public offerings. Pekarsky holds an M.B.A. in finance from Golden Gate University in San Francisco and a bachelor’s degree in accounting from Indiana University of Pennsylvania.


Anja Krammer                                                                                                                                    

A Silicon Valley veteran, Ms. Krammer has deep experience guiding healthcare and other enterprises to identify and fulfill unmet consumer needs. She has overseen marketing at diverse companies, such as aesthetic market leader Reliant Technologies, biomedical engineer Medtronic, print imaging manufacturer Tektronix and telecommunications giant AT&T. She has also counseled companies, such as American Express, GSK, Medicis Pharmaceuticals and Weight Watchers NA. Krammer graduated from the University of South Carolina and completed post-graduate studies at Webster University and the University of Paris – Sorbonne.

Kin F. Chan, Ph.D.                                                                                                                             

Dr. Chan is a serial biomedical entrepreneur who has developed novel, effective therapies for diverse medical conditions. His research and product development experience spans semiconductors, lasers/photonics, medical devices and biomedical sciences. He has therapeutic experience in dermatology, cardiology, urology and ophthalmology. Prior to BiopharmX, Chan was Vice President of Engineering at Demira, where he helped develop photodynamic therapies and directed advanced research at Solta Medical, where he helped create fractional photothermolysis technology. He is a co-inventor on more than 25 patents and pending patent applications. Chan holds a Ph.D. in electrical and computer engineering from the University of Texas at Austin, where he also achieved his bachelors and masters degrees.

Douglas Thomas, Ph.D.                                                                                                                     

Dr. Thomas has more than 20 years of experience in biopharmaceutical research, process development, manufacturing and commercial development in start-ups and Fortune 500 companies. His background includes 10 years in business development and more than 10 years in research and development. He has consulted extensively in innovative start-ups focused on the application of diverse hardware and software in the biopharmaceutical industry. He has worked with a variety of biomedical companies, including BioSys Laboratories, Calypte Biomedical, Millipore and Invitrogen Life Technologies. Thomas holds a Ph.D. in immunology from Baylor College of Medicine and a bachelor’s degree in pharmacology from the University of California, Santa Barbara.

Jack Kessler, Ph.D.                                                                                                                           

Dr. Kessler has more than 35 years of applied development experience in the area of iodine-based formulations, bio-analytical assays, in vitro diagnostic (IVD) medical devices and regulatory affairs. He is a named inventor on more than 20 U.S. patents for analytical assays, IVD medical devices, iodine-based disinfectants and formulations and pharmaceutical dosage forms. Kessler has also authored more than 20 publications and book chapters and participated on six federal research grants from the National Institute of Health and the U.S. Department of Agriculture. He received a doctorate in biochemistry from SUNY at Syracuse and a bachelor’s degree in chemistry from Stevens Institute of Technology in New Jersey.

AnnaMarie Daniels                                                                                                                             

Ms. Daniels is a microbiologist and biochemist by training and holds multiple patents. She has authored or contributed to dozens of peer reviewed articles and abstracts on subjects ranging from in vitro assays to breast cancer prevention. For the last 35 years she has held technical and executive level positions in start-up and development stage pharmaceutical and medical device companies working in the areas of implantable biomaterials, oncology, women’s health, pain, urology and interventional neuroradiology. She has been responsible for all aspects of company operations and has specific expertise in design and implementation of clinical and regulatory strategy for new product development. Prior to joining BioPharmX, she led the botulinum neurotoxin program at Johnson & Johnson, the clinical research program for Boston Scientific Neuromodulation and served as an independent consultant for a number of pharmaceutical and medical device companies.

Ross Portaro                                                                                                                                     

Mr. Portaro has 30 years of global sales executive experience in dermatology, women's health, and aesthetics. In dermatology, most recently as a sales director at Ulthera, he doubled sales and positioned them for their 2014 acquisition by Merz. At Medicis, Portaro led the LipoSonix team in Europe and facilitated the sale to Solta in 2011. In Women's Health, he built the original sales team at SenoRx, which was the leader in breast biopsies devices and had a successful 2007 IPO. In aesthetics, Mr. Portaro started TRIA Beauty as the Vice President of Sales and was the first medical laser executive to globally launch a medical-grade laser for hair removal into the consumer OTC Market. TRIA Beauty is positioned for a 2014 IPO. Mr. Portaro received his BS in Commerce from the McIntyre School of Commerce at the University of Virginia.
Stephen Morlock                                                                                                                                    
A seasoned financial executive and retail industry veteran, has been added to its board of directors.  Mr. Morlock's background will assist the company as it continues to expand its national roll-out of Violet iodine, the new, once-daily, non-prescription pill for relief of premenstrual breast discomfort, and he will serve as an independent board member on BioPharmX Corporation's audit, compensation and nominating and corporate governance committees.

Morlock previously served as executive vice president and chief financial officer from 1994 to 2004 at Otis Spunkmeyer, a baked goods distribution company that has successfully pursued distribution of its products to small family-owned businesses all the way up to large worldwide organizations, including the U.S. Army.  He served as controller there from 1992 to 1994.  He also has experience garnered from these roles in various aspects of the retail industry, including going to market via various distribution channels, product merchandizing, customer relationship management, brand development, manufacturing, procurement, and inventory management.   

"Stephen brings a unique blend of financial expertise and experience in the retail industry to BioPharmX," said Jim Pekarsky, chief executive officer and co-founder of BioPharmX Corporation.  "His expertise and experience will prove valuable as we continue retail distribution expansion for Violet iodine."

Prior to his roles at Otis Spunkmeyer, Morlock held various management positions in accounting, financial planning and internal auditing at Westinghouse Electric Supply Company from 1977 to 1991. He holds a B.S. degree in Accounting from San Diego State University


Corporate Headquarters

BioPharmX, Inc.
1098 Hamilton Court
Menlo Park, CA 94025

SEC Filings link below.

OneMed San Francisco 2014 Webcast http://www.onemedplace.com/onemedtv/play.php?vid=2570

2015 Second Quater Finacial Results Webcast http://78449.choruscall.com/dataconf/productusers/bpmx/media/bpmx150914a.mp3








Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#1497  Sticky Note BioPharmX Corporate Presentation Whos_Who 03/20/18 09:57:27 PM
#2464   yep getting hit hard.. but at this point kt1ao 05/20/19 03:35:13 PM
#2463   Yup, not ideal. Haha LeClair 05/20/19 01:45:43 PM
#2462   Yeah taking a serious beating. Get the defibrillator. PNW_Ironman 05/20/19 01:44:17 PM
#2461   Holding till earnings but who knows at this point... LeClair 05/20/19 01:42:11 PM
#2460   Hmmmm.... still waiting for that. PNW_Ironman 05/20/19 01:39:55 PM
#2459   Should be hitting $2-3 soon IMO LeClair 05/07/19 01:20:07 PM
#2458   Looks like things are starting to percolate figaruch 05/07/19 12:34:30 AM
#2457   * * $BPMX Video Chart 04-26-2019 * * ClayTrader 04/26/19 04:39:57 PM
#2456   Company’s Stockholders 2019 Annual Meeting Whos_Who 04/26/19 04:30:06 PM
#2455   BioPharmX Completes 1-for-25 Reverse Stock Split Whos_Who 04/26/19 04:26:46 PM
#2454   Folks keep forgetting that this is not an emz 04/24/19 09:27:00 AM
#2453   Wild action already today! Heavy volume! Whos_Who 04/24/19 09:23:22 AM
#2452   Far from over emz 04/24/19 09:17:57 AM
#2451   * * $BPMX Video Chart 04-23-2019 * * ClayTrader 04/23/19 06:34:47 PM
#2450   hype is over, take earnings Lilgreedy345 04/23/19 10:55:10 AM
#2449   That Exciting DrShocker 04/22/19 10:03:45 PM
#2448   Ya know! Once past this dreadful RS we Whos_Who 04/22/19 09:29:50 PM
#2447   Haha will do. Yes I am just hanging DrShocker 04/22/19 09:26:31 PM
#2446   Still hanging around, huh Dr? Let us know Whos_Who 04/22/19 09:15:46 PM
#2445   Hmmmm. How to play an R/S DrShocker 04/22/19 09:05:29 PM
#2444   I’m back in on a partial fill at GekkoSuit 04/16/19 06:30:31 PM
#2443   I agree- high risk/reward proposition here emz 04/16/19 02:08:36 PM
#2442   I hope you right there,but the last three Kra 04/16/19 12:16:41 PM
#2441   Way to set these guys straight. bubba03 04/16/19 11:36:14 AM
#2440   UCPA would never kill it's shareholders like this. Matthew12321 04/16/19 11:14:33 AM
#2439   Yeah, been burned on SL settings myself before. Whos_Who 04/15/19 11:21:33 PM
#2438   Yes, I stand corrected. My bad. Got GekkoSuit 04/15/19 11:13:01 PM
#2437   Agree- Also- this is not a stinky-pinky R/S emz 04/15/19 09:01:00 PM
#2436   IMO the price should stabilized back to the Whos_Who 04/15/19 07:34:46 PM
#2435   Very disappointed with this company. Let's hope Makeamillion 04/15/19 07:17:25 PM
#2434   This ol dog had way too many fleas! Whos_Who 04/15/19 06:08:26 PM
#2433   Totally agree. Personally, i wanted the R/S. Shareholders WallStreetSTTA 04/15/19 06:03:29 PM
#2432   Nobody wanted a R/S but that's where Anja Whos_Who 04/15/19 05:50:58 PM
#2431   Yeah, Friday the 26th we wake up with Whos_Who 04/15/19 05:46:15 PM
#2430   yeah i didn't think it was happening tomorrow. kt1ao 04/15/19 05:44:28 PM
#2429   Tomorrow? You mean 2 Fridays from today. (April Whos_Who 04/15/19 05:40:32 PM
#2428   After split, stock will be around $2.00 with Whos_Who 04/15/19 05:39:29 PM
#2427   Open tomorrow at about $2.24. It will drop GekkoSuit 04/15/19 05:38:35 PM
#2426   Bail, buy back after R/S but watch for GekkoSuit 04/15/19 05:34:50 PM
#2425   BioPharmX Announces Reverse Stock Split Whos_Who 04/15/19 04:29:35 PM
#2424   Well the reverse spilt 25-1 is happening. is kt1ao 04/15/19 04:21:17 PM
#2423   * * $BPMX Video Chart 04-10-2019 * * ClayTrader 04/10/19 05:03:33 PM
#2422   Clay Trader and his minions shorting the stock. LeBongTrey 04/10/19 11:17:04 AM
#2421   Great dd, thanks for sharing tradenride 04/09/19 05:05:16 PM
#2420   * * $BPMX Video Chart 04-09-2019 * * ClayTrader 04/09/19 04:48:39 PM
#2419   I hope not, but Probably to sell a Kra 04/09/19 10:00:07 AM
#2418   Any insights on why price and volume are dough_maker 04/09/19 09:20:13 AM
#2417   Still try to find some positive ways to Kra 04/03/19 07:16:06 AM
#2416   Thanks! When is the upcoming presentation? Do they dough_maker 03/29/19 04:27:16 PM
#2415   Think you're missing new ROTH investors negating need nokomis 03/29/19 03:50:22 PM